Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Stock Information for Calyxt Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Calyxt Inc.

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Adaptimmune Reports Q2 2024 Financial and Business Updates
Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Adaptimmune Reports Q1 2024 Financial and Business Updates
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.